DNA Sequencing Market Research Report Information By Product (Consumable, Instrument, and Service), By Application (Diagnostics, Biomarkers & Cancer, Reproductive Health, Personalized Medicine, and Forensics), By Technology (Semiconductor Sequencing, Sequencing by Ligation, and Pyrosequencing), By End-User (Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals & Clinics), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030.

Global DNA Sequencing Market Overview

The DNA Sequencing Market Size was valued at USD 2.3 billion in 2022 and is projected to grow from USD 2.5 Billion in 2023 to USD 4.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.20% during the forecast period (2023 - 2030). Rapid advances in sequencing technology and bioinformatics have enabled the identification of DNA variants. These advances also identified variants associated with increased disease risk. These are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

The sequencing of DNA is a method that uses extensive parallelization to sequence many DNA strands. Both Sanger's technique and non-Sanger methods of sequencing are used in this sequencing. The development of pharmacological treatments for cancer is accelerated by individualized targeted sequencing of tumors, which also discovers cancer targets or pathways. Introducing large-scale initiatives utilizing NGS techniques produces a fresh fundamental understanding of oncology precision therapy. Compared to microarray and other genetic analysis methods, DNA sequencing offers advantages such as excellent accuracy & speed, cheap cost, and accurate results even with limited sample input. Biomarker identification, forensic analysis, oncology research, and individualized healthcare are among the uses for DNA sequencing.

It has greatly outperformed more traditional genomics methods, including genotyping, microarray, and others, and has sped up the study of nucleotides. DNA sequencing, a highly accurate and high-throughput technology utilized for various applications, including WGS, de novo assembly, and DNA resequencing, has caused an upheaval in proteomic and genomic studies. As a result, several academic research institutions can utilize this technology for research investigations. Consumer call for DNA sequencing has significantly increased due to the surge in sequencing applications and growth in DNA sequencing technology. Additionally, a boost in worldwide genome mapping efforts and R&D spending drive the market's expansion.

Technology advancements in DNA sequencing, increased clinical diagnostics and drug development applications, and higher R&D spending influence market growth. Applications for DNA sequencing can be found in forensics, personalized medicine, biomarkers, reproductive health, and other fields. DNA sequencing technology has enormous potential in clinical research and development for cancer diagnostics and therapies. The ability of NGS, or next-generation sequencing, to find and characterize clinically relevant genetic variations across several genes in a single test has recently been established quickly and affordably.

News: PacBio and GeneDx, two leading providers of excellent, highly accurate sequencing solutions, jointly announced a research partnership with the University of Washington to examine the potential of HiFi long-read whole genome sequencing (WGS) for increasing the rate of pediatric patients receiving a diagnosis for genetic conditions. At Seattle Children's Hospital, 350 individuals, including 120 participants in the SeqFirst WGS trial and their biological parents—duos and trios—will have their samples subjected to WGS sequencing and analysis by GeneDx. To determine whether novel variations that were previously inaccessible by short-read sequencing methods may be the cause of some genetic disorders, both short-read and long-read WGS are going to be used.

DNA Sequencing Market Trends

• Increased technological advancement to boost the market growth

DNA sequencing technology can sequence multiple DNA strands through massive parallelization. Such sequencing includes Sanger sequencing and non-Sanger sequencing. Compared with microarrays and other genomic analysis methods, DNA sequencing has the advantages of low cost, high accuracy, high speed, and precise results, even with small sample input volumes. DNA sequencing is used to perform a variety of applications, such as biomarker discovery, oncology research, personalized medicine, forensics, and more. It simplifies nucleotide analysis and is a broad alternative to traditional genomics tools, notably microarrays, genotyping, and more. The demand for DNA sequencing has increased significantly owing to the proliferation of sequencing applications and the increase in technological advancements in DNA sequencing. Moreover, the surge in genome mapping initiatives and increasing investment in research and development across the globe drive market growth.

DNA sequencing has brought about a paradigm shift in proteomics and genomics research. It is a highly accurate and high-throughput technology used in various applications such as de novo assembly, WGS, and DNA resequencing. Therefore, the technology is quickly adopted by several academic research institutions for research. Illumina installed the NovaSeq 6000 Sequencing System at the Whitehead Biomedical Research Institute in Massachusetts, USA, in June 2020.

The market of DNA sequencing is driven by efforts by the Centers for Medicare & Medicaid Services (CMS), the Society for Molecular Pathology, and commercial payers such as Blue Cross Blue Shield and Aetna to facilitate the clinical use of sequencing technology. For example, in January 2020, China Medical System expanded the coverage of NGS-based diagnostic tests for ovarian and breast cancer patients, providing patients with more opportunities for personalized cancer care. Therefore, the market CAGR of DNA Sequencing has been increasing globally in recent years. These are essential factors driving the DNA Sequencing market revenue growth.

DNA Sequencing Market Segment Insights

DNA Sequencing Product Insights

Based on Product, the market segments of DNA Sequencing includes Consumables, Instruments, and Service. The consumable segment held the majority share in 2022, contributing most of the DNA Sequencing market revenue. The wide availability of reagents and kits for all library construction steps, such as DNA fragmentation, enrichment, adapter ligation, amplification, and quality control, contributes to a larger share of this segment. Most of these tools feature streamlined and simplified workflows, ready-to-use components, and compatibility with low-input and formalin-fixed specimens. The continuous availability and availability of reagents and kits have made WGS more accessible and affordable, driving the market of DNA sequencing.

DNA Sequencing Application Insights

Application has bifurcated the DNA Sequencing market data into diagnostics, biomarkers & cancer, reproductive health, personalized medicine, and forensics. Biomarkers & cancer have a considerable share of the market. The market is expected to grow over the forecast year owing to the increasing prevalence of cancer and advancements in next-generation sequencing technologies. However, the personalized medicine segment is expected to witness considerable growth in the next-generation sequencing market over the forecast period owing to surging demand for drug treatments, advancements in research and development in healthcare, and rising awareness of NGS testing in the pharmaceutical and biotechnology industries.

DNA Sequencing Technology Insights

The DNA Sequencing market segmentation has been divided based on Technology into Semiconductor Sequencing, Sequencing by Ligation, and Pyrosequencing. Sequencing by ligation accounted for the largest market share of the DNA Sequencing due to the widespread use of DNA sequencing platforms in sequencing scenarios. It is likely to continue to dominate throughout the forecast period.

DNA Sequencing End-User Insights

Based on End-User, the DNA Sequencing industry has been segmented into academic & government research institutes, pharmaceutical companies, biotechnology companies, and hospitals & clinics. The academic & government research institute segment is expected to contribute a higher market share due to the wide acceptance of Sanger techniques and NGS in academic and institutional research projects. Moreover, rising funding and investment plans increase these entities' demand for DNA sequencing products, leading to a more significant revenue share.

Figure 1 DNA Sequencing Market by End-User, 2022 & 2030 (USD billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

News: The most current findings come from the prospective research GEMINI, or Genomic Medicine in Ill Infants and Newborns, in which four hundred hospitalized newborns had their complete genomes sequenced and underwent targeted gene panel testing. Even though it took longer, whole-genome sequencing beat the targeted test at identifying the origin of an infant's symptoms, with a diagnosis rate of 49% as opposed to 27% for the smaller panel. One-fifth of the individuals saw modifications to their treatment, such as medical professionals choosing to use or forgo specific medications and surgical treatments.

DNA Sequencing Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. North American DNA Sequencing market, which accounted for USD 1.05 billion in 2022, is expected to exhibit a significant CAGR growth during the study period. Continuous technological development by major players, high investment in R&D, and availability of technologically advanced healthcare infrastructure have led North America to hold a leading market share in the DNA sequencing. Several government initiatives in the United States and Canada support drug development and cancer treatment research.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3 DNA SEQUENCING MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's DNA Sequencing market accounts for the second-largest market share. Increasing adoption of organic growth strategies, such as product launches by key players in the Region to expand product portfolios, is expected to drive market growth over the forecast period. For example, in December 2021, Swiss-based pharmaceutical company F. Hoffmann-La Roche Ltd announced the launch of the AVENIO Edge System to provide a fully automated, integrated sequencing solution. The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment, and quantification steps that provides integrated end-to-end control and reliable, consistently high-quality results. Further, the German market of DNA Sequencing held the largest market share, and the U.K. market of DNA Sequencing was the fastest-growing market in the European Region.

The Asia-Pacific DNA Sequencing Market is expected to grow at the fastest CAGR from 2022 to 2030. A growing customer base drives international companies to expand their business through strategic moves. A prominent California company has raised over $75 million to expand its desktop DNA sequencers to support the ongoing crisis of COVID-19. Moreover, the China market of DNA Sequencing held the largest market share, and the Indian market of DNA Sequencing was the fastest-growing market in the Asia-Pacific region.

DNA Sequencing Key Market Players & Competitive Insights

Major market players are spending a lot on R&D to increase their product lines, which will help the market of DNA Sequencing grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the DNA Sequencing industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the DNA Sequencing industry to benefit clients and expand the market sector. The DNA Sequencing industry has provided medicine with some of the most significant benefits in recent years. In the market of DNA Sequencing, major players such as Abbott Laboratories, Terumo Corporation, Cardinal Health Inc., Cardiva Medical Inc., Morris Innovative Inc., and others are working on expanding the market demand by investing in research and development activities.

Illumina, Inc. is an American biotechnology company headquartered in San Diego, California, serving over 140 countries. Illumina was founded on April 1, 1998, to develop, manufacture, and sell integrated systems to analyze genetic variation and biological function. The company offers a range of products and services for sequencing, genotyping, gene expression, and proteomics. On January 9, 2023, pharmaceutical company Illumina Inc. and Nashville Biosciences LLC, a wholly owned Vanderbilt University Medical Center (VUMC) subsidiary, announced an agreement with biopharmaceutical company Amgen to sequence the whole genome of DNA samples of approximately 35,000 samples. The protocol helps accelerate therapeutic development through genomics and builds superior clinical genomic datasets.

Also, F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company with two divisions Pharmaceuticals and Diagnostics. The shares of its holding company, Roche Holding AG, are listed on the six major Swiss exchanges. The company is headquartered in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the world's leading provider of cancer treatments. In May 2020, F. Hoffman-La Roche Ltd. announced the acquisition of Stratos Genomics to advance the development of Roche nanopore sequencers. Roche believes the acquisition helps address clinical research needs and, thus, patient needs.

Key Companies in the DNA Sequencing market include

• Agilent Technologies Inc.


• Thermo Fisher Scientific Inc.


• Illumina Inc.


• QIAGEN


• Hoffmann-La Roche Ltd.


• Oxford Nanopore Technologies Ltd.


• Macrogen Inc.


• Perkin Elmer Inc.


• Pacific Biosciences of California Inc.


• BGI, among others

DNA Sequencing Industry Developments

October 2022 PacBio announced the launch of two genome sequencing systems, the Revio long-read sequencing system, and the Onso short-read sequencing system. Deep learning methods have also been integrated into Revio to detect DNA methylation from routinely sequenced libraries.

March 2022 Element Biosciences revealed technical details of its long-awaited Aviti DNA sequencer. The new benchtop instrument uses sequencing-by-synthesis chemistry, which Element says reduces reagent usage, costing about $7 per gigabyte.

DNA Sequencing Market Segmentation

DNA Sequencing Product Outlook

• Consumable


• Instrument


• Service

DNA Sequencing Application Outlook

• Diagnostics


• Biomarkers & Cancer


• Reproductive Health


• Personalized Medicine


• Forensics

DNA Sequencing Technology Outlook

• Semiconductor Sequencing


• Sequencing by Ligation


• Pyrosequencing

DNA Sequencing End-User Outlook

• Academic & Government Research Institutes


• Pharmaceutical Companies


• Biotechnology Companies


• Hospitals & Clinics

DNA Sequencing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Scope:

DNA Sequencing Report Scope

Report Attribute/Metric	Details
Market Size 2022	USD 2.3 billion
Market Size 2023	USD 2.5 billion
Market Size 2030	USD 4.8 billion
Compound Annual Growth Rate (CAGR)	11.20% (2023-2030)
Base Year	2022
Market Forecast Period	2023-2030
Historical Data	2019 - 2021
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product, Application, Technology, End-User, and Region
Geographies Covered	North America, Europe, Asia Pacific, and Rest of the World
Countries Covered	The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Agilent Technologies Inc., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Oxford Nanopore Technologies Ltd., Macrogen Inc., Perkin Elmer Inc., Pacific Biosciences of California Inc., BGI.
Key Market Opportunities	New product launches and R&D Amongst major key Players.
Key Market Dynamics	Growing requirement of breeders for animals and plant production Development in technology It is increasing research and development.

Frequently Asked Questions (FAQ) :